Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trajan Group HoldingsASX:TRJ -10.00%32 3-Year EBITDA Growth Rate is 17.10% as of Dec. 2025, which is at its 10-year median of 17.10. GuruFocus rates ASX:TRJ with a GF Score™ of 32/100 and a GF Value™ of A$1.11 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 689 Medical Devices & Instruments companies, Trajan Group Holdings ranks better than 62.12% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 17.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Trajan Group Holdings was 17.10% per year. The lowest was 17.10% per year. And the median was 17.10% per year.
Trajan Group Holdings (ASX:TRJ) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Trajan Group Holdings 3-Year EBITDA Growth Rate Related Terms
ASX:TRJ vs ISRG, BDX, RMD: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Trajan Group Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trajan Group Holdings 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Trajan Group Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Trajan Group Holdings's 3-Year EBITDA Growth Rate falls into.
Trajan Group Holdings 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 17.10% mean?
Trajan Group Holdings (ASX:TRJ) has a 3-Year EBITDA Growth Rate of 17.10% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Trajan Group Holdings and its competitors. This is near median its historical median of 17.10. Over the past decade, Trajan Group Holdings' 3-Year EBITDA Growth Rate has ranged from 17.10 to 17.10. According to the industry distribution chart, Trajan Group Holdings ranks #261 out of 689 companies in the Medical Devices & Instruments industry, placing it in the top 37.9%.
Is Trajan Group Holdings' 3-Year EBITDA Growth Rate too high?
Trajan Group Holdings' current 3-Year EBITDA Growth Rate of 17.10% is near median its 10-year median of 17.10. Over the past 10 years, this metric has ranged from a low of 17.10 to a high of 17.10. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.70. Trajan Group Holdings' value of 17.10% is 122.1% above this industry median. Based on the distribution chart, Trajan Group Holdings ranks #261 out of 689 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Trajan Group Holdings has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trajan Group Holdings' 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Trajan Group Holdings ranks #261 out of 689 companies for 3-Year EBITDA Growth Rate. This puts Trajan Group Holdings in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.70. Trajan Group Holdings' value of 17.10% is 122.1% above this benchmark. Historically, Trajan Group Holdings' own 3-Year EBITDA Growth Rate has ranged from 17.10 to 17.10 over the past decade. While the company's 10-year median is 17.10 vs. the industry median of 7.70, Trajan Group Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.70, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trajan Group Holdings's current 3-Year EBITDA Growth Rate of 17.10% is 122.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Trajan Group Holdings and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trajan Group Holdings's current 3-Year EBITDA Growth Rate is 17.10%, which is near median its own 10-year median of 17.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trajan Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, Trajan Group Holdings (ASX:TRJ) is currently considered Possible Value Trap. The stock's GF Value™ is A$1.11, compared to a current price of A$0.18 — trading 83.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 17.10%, which is near median its 10-year median of 17.10 and 122.1% above the Medical Devices & Instruments industry median of 7.70. Trajan Group Holdings' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Trajan Group Holdings (ASX:TRJ), the current 3-Year EBITDA Growth Rate is 17.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trajan Group Holdings (ASX:TRJ) Overvalued in 2026?
Based on GuruFocus' analysis, Trajan Group Holdings stock appears to be undervalued.
The current stock price of A$0.18 is trading 83.8% below its estimated GF Value™ of A$1.11.
GuruFocus considers Trajan Group Holdings to be Possible Value Trap.
Key valuation signals for ASX:TRJ:
3-Year EBITDA Growth Rate: 17.10% (near median its 10-year median of 17.10)
GF Value™: A$1.11 vs. price of A$0.18 (83.8% below fair value)
Industry Position: 122.1% above the Medical Devices & Instruments median (#261 of 689)
No single metric tells the full story. See the ASX:TRJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trajan Group Holdings Ltd is a developer and manufacturer of analytical and life sciences products and devices, seeking to enrich human well-being through scientific measurement. Its current portfolio of products comprises products, devices and solutions that are used in the analysis of biological, food, and environmental samples. The Group now reports in three operating segments: Components and Consumables, Capital Equipment and Disruptive Technologies. Key revenue is generated from Components and consumables, which include parts, supplies, components, and consumable products worldwide. The Group operates in Asia (Malaysia, Japan and Australia and New Zealand (ANZ)), USA and Europe, Middle East, Africa, and India (EMEA).
32GF Score
Get the complete analysis for ASX:TRJ
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:TRJ has been successfully added to your 
